Inclusion criteria:

          1. Patients with histologically confirmed GBM and/or other glioma subtypes at the time of
             diagnosis or prior relapse.

          2. Written documentation of local or central laboratory determination of amplification or
             translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1,
             FGFR2,or FGFR3

          3. RANO defined tumor progression by MRI in comparison to a prior scan

          4. Patients must have received prior external beam radiotherapy and temozolomide.

        Exclusion criteria:

          1. History of another primary malignancy

          2. Prior or current treatment with a FGFR inhibitor

          3. Neurological symptoms related to underlying disease requiring increasing doses of
             corticosteroids

          4. Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously
             on an EIAED, the patient must be off of it for at least two weeks prior to study
             treatment.